Catalent, Inc. (NYSE:CTLT) Given Average Recommendation of “Hold” by Analysts

Catalent, Inc. (NYSE:CTLT) has been given an average rating of “Hold” by the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating. The average twelve-month target price among analysts that have covered the stock in the last year is $63.40.

A number of equities research analysts have commented on the stock. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. StockNews.com started coverage on shares of Catalent in a research report on Friday, December 27th. They set a “hold” rating on the stock. Finally, Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp raised its stake in Catalent by 1.5% during the third quarter. State Street Corp now owns 7,451,135 shares of the company’s stock valued at $451,315,000 after purchasing an additional 113,095 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after buying an additional 2,299,784 shares during the last quarter. Alpine Associates Management Inc. raised its position in shares of Catalent by 3.4% during the 3rd quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company’s stock valued at $129,082,000 after buying an additional 69,875 shares in the last quarter. Bank of Montreal Can lifted its holdings in shares of Catalent by 181.5% in the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock valued at $109,388,000 after acquiring an additional 1,169,044 shares during the last quarter. Finally, Marshall Wace LLP grew its position in Catalent by 5.1% in the second quarter. Marshall Wace LLP now owns 1,792,951 shares of the company’s stock worth $100,818,000 after acquiring an additional 86,533 shares in the last quarter.

Catalent Stock Performance

NYSE:CTLT opened at $63.48 on Friday. Catalent has a one year low of $41.15 and a one year high of $63.50. The business has a fifty day moving average price of $61.18 and a 200-day moving average price of $59.78. The firm has a market capitalization of $11.52 billion, a price-to-earnings ratio of -28.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.15. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the company earned ($0.10) EPS. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. Sell-side analysts forecast that Catalent will post 0.78 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.